Company Description
ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally.
It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.
The company also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin.
In addition, it operates source plasma collection facilities.
The company sells its products through independent distributors, sales agents, specialty pharmacies, and other alternate site providers.
ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.
| Country | United States |
| IPO Date | Oct 17, 2013 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 624 |
| CEO | Adam S. Grossman |
Contact Details
Address: 465 State Route 17 Ramsey, New Jersey United States | |
| Website | https://www.admabiologics.com |
Stock Details
| Ticker Symbol | ADMA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001368514 |
| CUSIP Number | 000899104 |
| ISIN Number | US0008991046 |
| Employer ID | 56-2590442 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Adam S. Grossman | Co-Founder, President, Chief Executive Officer & Director |
| Brad Tade | Chief Financial Officer & Treasurer |
| Kaitlin Kestenberg | Chief Operating Officer & Senior Vice President of Compliance |
| Cindy Petersen | Vice President of Human Resources |
| Dr. Jerrold B. Grossman D.P.S., Ph.D. | Co-Founder & Vice Chairman of the Board |
| Drew Pantello | Vice President of Marketing & Corporate Development |
| John Hafl | Executive Director of Sales |
| Skyler Bloom | Senior Director of Business Development & Corporate Strategy |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 02, 2024 | 4 | Filing |
| Nov 22, 2024 | 4 | Filing |
| Nov 22, 2024 | 4 | Filing |
| Nov 21, 2024 | 8-K | Current Report |
| Nov 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 08, 2024 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Nov 07, 2024 | 10-Q | Quarterly Report |
| Nov 07, 2024 | 8-K | Current Report |
| Nov 04, 2024 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Oct 31, 2024 | 8-K | Current Report |